Beplex

Release form, composition and packing Beplex 
Solution for injection 1 ml 1 amp. thiamin (as hydrochloride) 5 mg 10 mg Riboflavin 2 mg, 4 mg pyridoxine (as hydrochloride) 2 mg, 4 mg cyanocobalamin 4 micrograms 8 mg dexpanthenol 3 mg 6 mg Nicotinamide 20 mg 40 mg. Inactive ingredients: polysorbate 80, benzyl alcohol, water, d / and.

Clinico-pharmacological group: Multivitamins.

Pharmacological action

Multivitamin preparations containing vitamins B, the pharmacological effect is due to the properties of its constituent vitamins. Thiamin (vitamin B1) as a coenzyme involved in the metabolism of carbohydrates, amino acids, the synthesis of RNA / DNA, bile acids, neurotransmitters. Riboflavin (vitamin B2) - an important catalyst of cellular respiration and visual perception.

Provides most of the redox reactions involved in metabolism of carbohydrates, fats and amino acids.

Pyridoxine (vitamin B6) as a coenzyme involved in the metabolism of amino acids and proteins in the synthesis of neurotransmitters.

Cyanocobalamin (Vitamin B12), together with folic acid is involved in the synthesis of nucleotides, involved in the formation of red blood cells and nerve cell membranes necessary for the growth of the organism.

Nicotinamide (vitamin PP, vitamin B3) is involved in tissue respiration, metabolism of fats, carbohydrates, amino acids.

Dexpanthenol (Vitamin B5) as an integral part of coenzyme A plays an important role in the processes of acetylation and oxidation of carbohydrates and fats, synthesis of bile acids, the synthesis of hormones.

Pharmacokinetics

Data on the pharmacokinetics of the drug Bepleks not given.

Statement
unbalanced diet;
malabsorption of vitamins in the intestine (sprue, diarrhea, and prolonged antibiotic therapy);
Prevention and treatment of neurological diseases (including neuritis, radiculitis, neuralgia, peripheral paralysis, diabetic polyneuropathy);
neurological disorders caused by chronic alcoholism;
diseases of the oral mucosa (glossitis, gingivitis, stomatitis);
digestive diseases (gastritis, gastric ulcer and duodenal ulcer, chronic colitis);
liver disease (including chronic hepatitis);
skin diseases (long-term non-healing wounds, burns, cracks in the corners of the mouth);
ophthalmic diseases (conjunctivitis, iritis, corneal ulcer, cataract);
metabolic disorders;
anemia;
pregnancy;
Lactation (breastfeeding).

Dosing regimen

The drug is prescribed in a / m / in adults and children over 12 years of 2-4 ml / day.

Side effect

Possible: an allergic reaction.

Contraindications
increased sensitivity to the B vitamins;
concurrent levodopa therapy.

Pregnancy and lactation

In applying Bepleksa at recommended doses were observed any negative effects on the fetus. In high doses, pyridoxine violates the release of prolactin, so the drug should be used with caution during lactation.

Cautions

Keep in mind that when receiving Bepleksa possible staining of the urine in yellow color, that due to the presence of the drug riboflavin. Efficacy of the drug in excessive doses for different diseases is not justified.

Overdose

Symptoms: nausea, vomiting, pale skin.

Treatment: symptomatic therapy.

Drug Interactions

Pyridoxine, which is part of the preparation Bepleks may increase the metabolism of levodopa, reducing the therapeutic activity of this drug. Joint application Bepleksa and levodopa is possible only with concomitant administration of inhibitors of decarboxylase.

Pyridoxine may decrease the effects of steroid hormones. Isoniazid increases the excretion of pyridoxine in the urine. Cycloserine, hydralazine, and penicillamine are antagonists of thiamine, which is part of the preparation Bepleks. Not recommended simultaneous use of the drug Bepleks with derivatives of HMG-CoA reductase inhibitors (lovastatin, pravastatin), because the interaction of these drugs is possible rhabdomyolysis.

Conditions and terms of

The drug should be stored out of reach of children, protected from light at temperature above 25 ° C. Do not freeze. Shelf life - 3 years.

Bepasal

Release forms - tablets (mikropachki) Bepasal 

Pharmacotherapeutic group - antispasmodic

Pharmacological action
antiseptic
m-anticholinergic
spasmolytic

Ingredients - fenilsalitsilat 0.3 g, papaverine hydrochloride, 30 mg, 12 mg of belladonna extract

Statement
Diseases of the digestive
Diseases of the esophagus, stomach and duodenum
Liver disease
Diseases of the gallbladder, biliary tract and pancreas
Noninfectious enteritis and colitis
Other diseases of intestines
Other diseases of the digestive system

The composition of the components
belladonna extract
papaverine
fenilsalitsilat

Application

Prescribe for diseases of the gastrointestinal tract as an antispasmodic, holinoliticheskoe and antiseptic.

Dosing regimen

1 tablet 2-3 times daily.

Bepanten Plus

Release form, composition and packing Bepanten Plus 

Cream for external use only homogeneous, opaque, white to pale yellow, with a weak specific odor. 1 g dexpanthenol 50 mg chlorhexidine hydrochloride 5 mg. Excipients: D, L-pantolactone, cetyl alcohol, stearyl alcohol, lanolin, white soft paraffin, liquid paraffin, polyoxyl 40 stearate, purified water.

Clinico-pharmacological group: drug with antimicrobial, anti-inflammatory and improves tissue regeneration effect for outdoor use.

Pharmacological action

Drug with antimicrobial, anti-inflammatory and improves tissue regeneration effect for outdoor use.

Chlorhexidine - an antiseptic that is active against bacteria which are normally on the skin or made on the skin as a result of contamination of the wound. Dexpanthenol in skin cells is rapidly converted to pantothenic acid, which plays an important role in the formation and in healing of damaged skin.

The drug reduces pain due to cooling effect. When applied to the wound surface protects against infection, promoting healing. Easily applied and washed off. Cream low-fat and does not stick.

Pharmacokinetics

Data on the pharmacokinetics of the drug plus Bepanten not given.

Statement
minor wounds with the threat of infection (abrasions, scratches, minor cuts and scratches, fractures, minor burns);
infected superficial lesions;
cracked nipples during breastfeeding;
chronic wounds (eg, trophic ulcers of lower leg, pressure sores);
surgical wound.

Dosing regimen

The cream is applied thinly once or several times a day on clean wound surface or on inflamed skin.

Treatment of wounds can be conducted as an open manner and with the use of bandages.

Side effect

Allergic reactions: a possible rash, itching.

Contraindications
processing or treatment of the ear;
in the case of heavy, deep and dirty wounds (such injuries require medical intervention);
hypersensitivity to the drug.

Pregnancy and lactation

The drug can be used during pregnancy and lactation, but should avoid its use on large areas of skin.

Cautions

Avoid getting the cream in the eye. Can not be taken orally. Large area, highly contaminated, and deep wounds, and bite and puncture wounds require medical attention (because of the risk of tetanus).

If the size of the wound for some time remain consistently high or wound does not heal within 10-14 days, it is necessary to consult a doctor.

This is necessary and if the wound is strongly hyperemic, the wound swells and suddenly appear in great pain or injury is accompanied by fever (due to the risk of sepsis).

Overdose

Data on drug overdose Bepanten plus not provided.

Drug Interactions

As a precaution for a possible interaction (antagonism or inactivation) should not be used Bepanten plus simultaneously with other antiseptics.

Conditions and terms of

The drug should be stored in a place inaccessible to children at a temperature not exceeding 25 ° C. Shelf life - 3 years.

Bepanten

Release form, composition and packing Bepanten 

The drug is approved for use as a means OTC.

Cream 5% soft, elastic, homogeneous, opaque, white to pale yellowish-white, with a weak specific odor.

1 g - dexpanthenol - 50 mg.

Excipients: D, L-pantolactone, phenoxyethanol, amfizol K, cetyl alcohol, stearyl alcohol, lanolin, isopropyl myristate, propylene glycol, purified water.

Ointment 5% uniform, homogeneous, soft, elastic, ranging from white to pale yellow. 1 g - dexpanthenol - 50 mg

Excipients: protegin X, cetyl alcohol, stearyl alcohol, lanolin, beeswax white, soft white wax, almond oil, liquid paraffin, purified water.

Clinico-pharmacological group: drug improves trophic and tissue regeneration, for outdoor use.

Benfolipen

Release form, composition and packing Benfolipen 

Tablets, film-coated white or nearly white. 1 tab. benfotiamine 100 mg of pyridoxine hydrochloride (vit. B6) 100 mg Cyanocobalamin (vit. B12) 2 mcg. Excipients: karmelloza (carboxymethylcellulose), povidone (Kollidon 30), microcrystalline cellulose, talc, calcium stearate (calcium octadecanoate), polysorbate 80 (Tween 80), sucrose. The composition of the shell: giproloza (hydroxypropylcellulose), macrogol (polyethylene 4000), povidone (polyvinylpyrrolidone low-molecular-medical), titanium dioxide, talc.

Clinico-pharmacological group: Combination of vitamins Group B.

Pharmacological action

Combined multivitamin complex. Effect of the drug determined by the properties of vitamins involved in its composition.

Benfotiamine - soluble form of thiamin (vitamin B1), is involved in conducting nerve impulses.

Pyridoxine hydrochloride (vitamin B6) is involved in the metabolism of proteins, carbohydrates and fats needed for normal blood, the functioning of the central nervous system and peripheral nervous system. Provides synaptic transmission, the braking process in the CNS, is involved in the transport of sphingosine, which is part of the nerve membrane, is involved in the synthesis of catecholamines. Cyanocobalamin (Vitamin B12) is involved in the synthesis of nucleotides is an important factor for normal growth, hematopoiesis, and development of epithelial cells, is required for the metabolism of folic acid and synthesis of myelin.

Pharmacokinetics

Effect of the drug is the combined effect of its components, so the holding of the kinetic observations is not possible, all the components together can not be traced with the help of markers or bio-research.

Statement

It is used in the treatment of these neurological diseases:
trigeminal neuralgia;
neuritis of the facial nerve;
pain caused by spinal cord injuries (including intercostal neuralgia, sciatica, lumbar syndrome, cervical syndrome, cervico-brachial syndrome, radicular syndrome, caused by degenerative changes of spine);
polyneuropathy of different etiologies (diabetic, alcoholic).

Dosing regimen

The drug should be taken after meals, not liquid and squeezed a small amount of liquid. Adults appointed on 1 tab. 1-3 times per day. Course duration - on doctor's advice. Not recommended treatment with high doses of the drug over 4 weeks.

Side effect

Allergic reactions: itching, urticaria rash.

Other: in some cases - increased sweating, nausea, and tachycardia.

Contraindications
severe and acute form of decompensated heart failure;
Infancy;
hypersensitivity to the drug.

Pregnancy and lactation

Benfolipen contains 100 mg of vitamin B6 and therefore during pregnancy and lactation (breastfeeding), the medication is not recommended.

Cautions

During the administration of the drug is not recommended taking multivitamin complexes containing B vitamins

Overdose

Symptoms: increased symptoms of side effects of the drug.

Treatment: gastric lavage, taking activated charcoal, the appointment of symptomatic therapy.

Drug Interactions

Levodopa reduces the effect of therapeutic doses of vitamin B6. Vitamin B12 is not compatible with heavy metal salts. Ethanol dramatically reduces the absorption of thiamine.

Conditions and terms of

The drug should be kept in the dark, dry, place inaccessible to children at a temperature not exceeding 25 ° C. Shelf life - 2 years.

Benfogamma 150

Release form, composition and packing Benfogamma 150 

Dragees white color and shiny, round, biconvex.

1 pills benfotiamine 150 mg.

Excipients: microcrystalline cellulose, povidone (K30), glycerides of fatty acids, colloidal silicon dioxide, karmelloza sodium, talc, shellac, sucrose, calcium carbonate, acacia powder, corn starch, titanium dioxide, silicon dioxide, anhydrous, macrogol 6000, glycerol 85% , polysorbate 80, beeswax mountain glycol.

Clinico-pharmacological group: Fat-soluble form of vitamin B1.

Pharmacological action

Pharmacotherapeutic group - a means to regulate metabolic processes. Vitamin preparation.

Benfotiamine has a B1 vitamin activity. Involved in carbohydrate metabolism (as a coenzyme) helps normalize nervous system functions.

Statement
hypovitaminosis and vitamin deficiency of vitamin B1. In the combined therapy of atherosclerosis, coronary heart disease, chronic circulatory failure, viral hepatitis, dermatosis, functional disorders of the nervous system.

Dosing regimen

Before use, check with your doctor. To 1 tablet once a day with plenty of fluids.

The treatment course of 15-30 days. Repeated courses of 2-3 months (on doctor's advice).

Side effect

Possible allergic reaction (hives, itchy skin).

Contraindications
hypersensitivity to components of the drug.

Cautions

Side effects occur more frequently in menopausal women and patients with chronic alcoholism.

The daily need for vitamin B1 for men - 1.2-2.1 mg for the elderly - 1.2-1.4 mg for women - 1.1-1.5 mg for children - 0.3-1.5 mg.

Overdose

Information about the overdose was not provided.

Conditions and terms of

Keep out of reach of children at or above +25 C. Shelf life - 5 years.

Benzydamine

The active substance (INN) Benzidamin (Benzydamine)

Application Benzidamin (Benzydamine)

Inflammatory condition of the mouth and throat: pharyngitis, aphthous ulcers, gingivitis, stomatitis, tonsillitis, posttonzillektomicheskie condition, inflammation of the oral mucosa after radiotherapy and chemotherapy, surgery, lower limb venous insufficiency, including during pregnancy, phlebitis and thrombophlebitis of superficial veins of legs (combined therapy), state after sclerosing of the veins and phlebectomy, postflebitnye syndromes, nonspecific vaginitis (before and after surgery in the vaginal area, after radiotherapy, the use of intrauterine pessaries), fungal and trichomonazice, inflammation in the cervix, estrogen therapy for atrophied vagina in old age.

Contraindications

Benzidamin (Benzydamine): Hypersensitivity; for a solution - children's age (12 years) for tablets - phenylketonuria.

Side Effects

Numbness tissue and burning sensation in the mouth (lingual tablets), dry mouth, drowsiness, and allergic reactions (skin rash).

Dosing and Administration

Gargarism or oral - 15 ml (1 tbsp) every 1,5-3 hours (do not swallow).

Tablets - 3 mg 3-4 times a day (keep in his mouth to complete resorption).

Aerosol (shown in elderly patients or in the postoperative period for failure to rinse your mouth) every 1,5-2 hours - adults and elderly patients - 4-8 doses for children 6-12 years - 4 doses, children under 6 years - 1 dose per 4 kg body weight (maximum - 4 doses).

Vaginal washing 1-2 times a day: powder (1 sachet) was dissolved in 500 ml of water (the solution should be warm) and for single use douching 140 ml, the procedure is carried out in prone, the liquid should remain in the vagina for several minutes.

The gel is applied to affected skin 2-3 times a day and gently rub until completely absorbed.

Precautionary measures

When you apply the gel to avoid it falling on the mucous membranes. Long-term (more than 7 days) treatment should be carried out under the supervision of a physician.

Designate caution during pregnancy and breastfeeding (pills, spray, powder, solution). Avoid getting spray into eyes.

Benatex

Release form, composition and packing Benatex 

Vaginal suppositories from white to white with a yellowish shade, torpedo-shape. 1 supp. benzalkonium chloride 9.18 mg. Excipients: vitepsol.

Clinico-pharmacological group: Vaginal contraceptive with spermicidal activity.

Pharmacological action

Vaginal contraceptive with spermicidal activity, is also antiseptic, antifungal, antiprotozoical action, inactivate the virus Herpes simplex.

The drug is active against gram-positive bacteria (including Staphylococcus spp., Streptococcus spp.); Gram-negative bacteria (including Escherichia coli, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Proteus spp., Klebsiella spp.); Anaerobic bacteria fungi and molds.

Also active against bacterial strains resistant to antibiotics and other chemotherapeutic drugs, inhibits hyaluronidase plazmokoagulazu and staphylococci. Spermicidal effect of the drug due to the ability to damage the sperm membrane (at the beginning of the flagella, then the head), which accounts for the impossibility of fertilization damaged sperm.

Effect develops within 5 min after administration of a vaginal suppository. Is active in the prevention of sexually transmitted infections (including gonorrhea, chlamydia, trichomoniasis). Not affect the normal vaginal microflora (including wand Dederleyna) and the hormonal cycle.

Pharmacokinetics

The drug is practically not absorbed by intravaginal administration, removed a simple cleaning the water and with normal physiological discharge.

Statement

Local contraception for women of reproductive age:
with contraindications to the use of oral contraceptives or intrauterine contraceptive;
in the postpartum period;
lactation;
in the period after termination of pregnancy;
in premenopauzny period;
if necessary, episodic prevent pregnancy;
while skipping or delay in receiving consistently used oral contraceptives.

Dosing regimen

Pre-releasing suppository from the contour package, it is introduced deep into the vagina in the supine position for 5 minutes before intercourse. Single dose: 1 suppository is designed for a sexual act.

The duration of drug action is 4 pm Be sure to enter a new vaginal suppository in repeated sexual acts. Multiplicity of limited individual tolerance of the active substance and the frequency of sexual acts.

Side effect

Allergic reactions.

Contraindications
coleitis;
ulceration and irritation of the mucous membrane of the uterus and vagina;
hypersensitivity to the drug.

Pregnancy and lactation

The drug may be used during pregnancy because it has no harmful effect on pregnancy. The drug may be used during breast-feeding because it is not excreted in breast milk.

Cautions

To improve the efficiency requires careful adherence to a method of using the drug. Can be used in conjunction with a vaginal diaphragm or an intrauterine contraceptive.

After sexual intercourse is not recommended intravaginal use feminine hygiene products (soap and water douche, because the soap breaks down the active drug substance) to avoid loss of contraceptive effect; possible outdoor toilet sex organs.

Overdose

Data on drug overdose are not given.

Drug Interactions

Any drug introduced intravaginally, can reduce local spermicidal action (including soaps and solutions containing it). Iodine solution (including 0.1% solution yodonata) inactivate the drug.

Conditions and terms of

List B. The drug should be kept away from children, dry, dark place at temperatures not above 20 ° C. Shelf life - 2 years.

Benarin

Release form, composition and packing Benarin 

Nasal drops 0.05% as a clear, colorless or slightly yellowish liquid, allowed easy opalescence. 1 ml of budesonide 500 mcg. Other ingredients: propylene glycol, polyethylene 400, benzoic acid, succinic acid, Trilon B, thiourea, nipazol, purified water. Generic international name, recommended by WHO, the Russian Federation agreed to write the international name - budesonide.

Clinico-pharmacological group: SCS for intranasal use.

Pharmacological action

SCS for intranasal use. Has anti-inflammatory, antiallergic and immunosuppressive effect. Increases the production lipomodulina, an inhibitor of phospholipase A, inhibits the release of arachidonic acid. Warns edge aggregation of neutrophils, reduces inflammatory exudation and production of lymphokines, inhibits the migration of macrophages, reduces the intensity of infiltration and granulation formation of chemotactic substances. Reduces the swelling of the nasal mucosa, the production of mucus. Improves mucociliary transport. Well tolerated during prolonged therapy, has almost no systemic effects, has no mineralocorticoid activity.

Pharmacokinetics

Absorption, distribution and metabolism

In the application of nasal drops absorption of budesonide is low. Ranked in the gastrointestinal tract of budesonide (90%) subjected to the effect of "first passage" through the liver to form inactive metabolites. Bioavailability of 10% for that part of the drug, which came in the gastrointestinal tract. Cmax is reached 15-45 minutes after intranasal application, and is 0.01 mg / dL. Plasma protein binding - 88%.

Breeding

Has a high systemic clearance - 84 l / h. T1 / 2 - 2.8 hours out through the intestines as a metabolite - 10%, kidney - 70%.

Statement
seasonal allergic rhinitis;
perennial allergic rhinitis.

Dosing regimen

Benarin assign adults (patients older than 18 years). Single dose intranasal application depends on the severity of the disease and is 60-120 mg (2-3 drops in each nostril). The daily dose is selected individually according to the severity of rhinitis.

As a rule, enough 2 single doses per day. The duration of maintenance therapy is determined individually. The maximum single dose is 200 mcg (100 mcg in each nostril) and a maximum daily dose - 400 micrograms for a period not exceeding 3 months.

Side effect

Maybe: burning, irritation, nasal mucosa, sneezing, kandidomikoz.

Contraindications
fungal, bacterial and viral infections of the respiratory system;
pulmonary tuberculosis;
hypersensitivity to the drug.

Pregnancy and lactation

Health & Safety Benarina during pregnancy and lactation is not currently installed.

Cautions

Using the drug should be avoided from dripping into his eyes.

Overdose

Symptoms: prolonged use Benarina in high doses, as well as simultaneous administration of corticosteroids for systemic use may develop symptoms of hypercortisolism.

Treatment: the phasing out of the drug.

Drug Interactions

With the simultaneous application of phenobarbital, phenytoin, rifampin reduce the effectiveness of budesonide (due to induction of enzymes of microsomal oxidation). Methandrostenolone and estrogens enhance the effect of budesonide.

Conditions and terms of

The drug should be stored in a dry place, protected from light and away from children at or above 25 ° C. Shelf life - 2 years.

Benalgin

Release form, composition and packing Benalgin 

The tablets are round, flat, white, with the dividing line on one side.

1 tab.

metamizol sodium 500 mg.

Caffeine 50 mg.

thiamine hydrochloride, 38.75 mg.

Other ingredients: gelatin, wheat starch, microcrystalline cellulose, colloidal silicon dioxide, talc, magnesium stearate.

Clinico-pharmacological group: analgesic-antipyretic combination composition.

Pharmacological action

Part of the drug metamizol sodium possesses analgesic, antipyretic and anti-inflammatory effects associated with inhibition of prostaglandin synthesis primarily in the central nervous system and increased production of beta-endorphins. Caffeine has some protivomigrenoznoe (tones the blood vessels of the brain) and the stimulating effect: it excites the vasomotor center, promotes efficiency, reduces fatigue and sleepiness. Thiamine hydrochloride (vitamin B1) is involved in the metabolism and enhances neyroreflektornoy regulation.

Statement
moderately or weakly expressed pain syndrome (headache, toothache, migraine pain, neuralgia, myalgia, arthralgia, with radicular syndrome, and dysmenorrhea);
for weak pains of visceral origin (renal, biliary colic, spasms of the intestine) in combination with atropinopodobnymi or antispasmodic;
fever with colds and other infectious and inflammatory diseases (at diagnosis).

Usefulness of the drug is solved in each case depending on the severity, nature and portability of a fever.

Dosing regimen

Applied inside after a meal and 1 tablet 2-3 times in the first half of the day. The maximum single adult dose of 2 tablets daily - 6 tablets (not more than 1-2 days). Duration receiving no more than 5 days. Increasing the daily dose or duration of treatment is possible only under medical supervision.

Dosages for children. Children aged 12 to 16 years - half or one tablet 2-3 times per day, maximum daily dose of 4 tablets.

Side effect

At therapeutic doses, the drug is generally well tolerated. Sometimes possible allergic reactions (skin rash, itching, angioedema, rare - anaphylactic shock). With long-term use may breach by the system of blood (thrombocytopenia, leukopenia, agranulocytosis). The propensity to bronchospasm may provoke an attack. There are sleep disturbances, palpitations, cardiac arrhythmias.

Symptoms of acute poisoning: nausea, vomiting, stomach pain, mental and motor agitation, tachycardia, cardiac arrhythmia, possibly reducing urine output, epileptiform convulsions. Should immediately seek medical help. The victim should do a gastric lavage, appoint adsorbents. If necessary, symptomatic treatment.

Contraindications
hypersensitivity to thiamine, caffeine, analgin and other pyrazolone derivatives (phenylbutazone, tribuzon);
expressed in human liver or kidney problems;
bronchospasm;
genetic absence of glucose-6-phosphate dehydrogenase;
diseases of the blood system;
insomnia;
severe hypertension;
significant signs of atherosclerosis;
intraocular pressure;
during pregnancy and breastfeeding;
Children up to age 12 years;
pregnancy and lactation;
receiving the drug banned.

Cautions

While taking the drug in the afternoon may be a sleep disorder in the form of sleep disorders.

With caution and under medical supervision to patients with impaired liver or kidney disease.

With long-term (more than a week) use of the drug to be controlled pattern of peripheral blood and liver functional state.

Drug Interactions

The simultaneous use of Analgin with other non-narcotic analgesics, nonsteroidal anti-inflammatory drugs can lead to mutual reinforcement of toxic effects. Tricyclic antidepressants, contraceptives for oral administration, allopurinol violate metabolism analgin in the liver and increases its toxicity. Barbiturates, phenylbutazone and other inducers of liver enzymes reduces the effect of Analgin. The simultaneous use of Analgin with cyclosporine decreases the level of the latter in the blood. Sedatives and tranquilizers increase the analgesic effect of Analgin.

In combination with the above Benalgina and other drugs should consult a doctor and surveillance

Conditions and terms of

Store in a dry and dark place at 15-25 ° C., the reach of children.

Shelf life - 3 years.

Benacort

Release form, composition and packing Benacort 

Powder for inhalation fine grained, white or nearly white. 1 dose of budesonide 200 mcg * Excipients: sodium benzoate.

Solution for inhalation is colorless or slightly yellow, to light opalescence. 1 ml of budesonide * 250 mcg. Excipients: Nipagin, succinic acid, Trilon B, polyethylene 400, propylene glycol, purified water.

Solution for inhalation is colorless or slightly yellow, to light opalescence. 1 ml of budesonide 500 mcg. Excipients: Nipagin, succinic acid, Trilon B, polyethylene 400, propylene glycol, purified water. Generic international name, recommended by WHO, the Russian Federation agreed to write the international name - budesonide.

Clinico-pharmacological group: corticosteroids for inhalation.

Pharmacological action

Corticosteroids for inhalation use. Has anti-inflammatory, antiallergic and immunosuppressive effect. Increases the production lipomodulina, an inhibitor of phospholipase A, inhibits the synthesis of arachidonic acid and products of its metabolism (cyclic endoperoksidov and prostaglandins).

Warns edge aggregation of neutrophils, reduces inflammatory exudation and production of cytokines, inhibits the migration of macrophages, reduces the intensity of infiltration and granulation formation of chemotactic substances, inhibits the release of mast cell inflammatory mediators. Increases the number of active β-adrenergic receptors, eliminating their desensitization (restores the patient response to bronchodilators, can reduce the frequency of their use), reduces swelling of bronchial mucosa, mucus production and reduces airway hyperresponsiveness. Improves mucociliary transport. Well tolerated for prolonged use, has no mineralocorticoid activity, almost no resorptive action. Improved lung function after a few hours after a single dose solution for inhalation (using an inhaler). However, the therapeutic effect develops only after several days of regular use at recommended doses (average 5-7 days). The drug is designed to prevent asthma attacks, and not for acute bronchospasm.

Pharmacokinetics

Absorption and distribution

Systemic absorption of the drug is low. After inhalation of 20-25% reaches the small bronchi, part of the dose that gets into the digestive tract, and almost completely absorbed (90%), biotransformed in the liver to inactive metabolites. Bioavailability of the powder for inhalation is 10% for that part of the dose, which reached the gastrointestinal tract, and 28% - for a fraction of the lung. Bioavailability solution for inhalation is 38%, and 1 / 6 of this magnitude is formed due to ingestion of the drug. Cmax of budesonide in plasma is reached 15-45 minutes and is 0.01 mg / dL. Plasma protein binding is 88%. Vd is 3 L / kg.

Breeding

Has a high plasma clearance - 84 l / h. T1 / 2 inhalation route of administration is 2.8 h. Write up to 10% - through the gut in the form of metabolites, 70% - kidneys.

Pharmacokinetics in special clinical situations

Patients with impaired liver function may increase the time spent budesonide in the body.

Statement
asthma (as an antiinflammatory therapy, with lack of effectiveness of bronchodilators and / or cromoglicic acid to reduce the dose of oral corticosteroids);
chronic obstructive pulmonary disease with the proven efficacy of SCS.

Dosing regimen

Powder for inhalation

Inhalation Benakorta conduct by an individual portable inhaler Tsiklohaler. The daily dose is determined individually according to the severity of bronchial asthma and the maintenance dose of oral corticosteroids. The recommended starting dose is 400-1600 mg / day maintenance - 200-800 mcg. During exacerbation of bronchial asthma dose can be increased to 800-1600 mg / day. The maximum daily dose - 2000 mg. The daily dose is administered over 2-4 inhalations. The duration of treatment to 3-12 months, depending on the severity of asthma. When hormone-dependent asthma with oral corticosteroids to move to the therapy.

Benakortom should be in a stable phase of the disease, with the first 14-20 days should be combined with the continuation of inhalation Benakorta GCS inside. Then a dose of oral corticosteroids is gradually reduced, until the complete withdrawal (if available).

Rules of the inhaler "Tsiklohaler"

Remove the protective cover, shake the inhaler, push dispenser from the housing inhaler to stop and knock on the grounds dispenser palm, then push the dispenser into the body. Make a full exhalation. Insert the mouthpiece into your mouth and make him a deep and strong breath. Remove the inhaler from the mouth and hold your breath for 10 seconds. When you exhale the exhaled air must pass through an inhaler. If necessary, make repeated inhalation through an inhaler. After the procedure, the inhaler wear a protective boot.

Solution for inhalation

Benakort in the form of solution for inhalation use only through the nebulizer. The dosage regimen set individually. The recommended starting dose for adults is 1-2 mg / day maintenance dose - 0.5-4 mg / day. On reaching effect dose is gradually reduced to the minimum effective, needed to maintain a stable state. In some cases it is possible to use the drug in higher doses (if necessary, a more rapid achievement of therapeutic effect).

Go to the GCS inside to therapy

Benakortom possible in a stable phase of disease (in this case within 10-14 days of combined inhalation and GCS in, then gradually reduce the dose of oral corticosteroids up to a full withdrawal). 1 vial contains a single dose.

Rules of the nebulizer

Open the vial. Fill in the nebulizer through the upper hole necessary amount of the drug. Nebulirovanie produced in accordance with the instructions for the type of nebulizer. Solution for inhalation can be diluted with 0.9% sodium chloride. Volume of the solution of budesonide delivered to the patient's lungs using the nebulizer, is variable and depends on several factors (including time of inhalation, the level of filling chamber specifications nebulizer, individual characteristics of the patient's respiratory function, the use of a mouthpiece or mask).

If you use a mask, make sure that the inhalation mask fits snugly to the face, the face should be washed after inhalation. After each inhalation should rinse your mouth with water. Nebulizer chamber and mouthpiece or mask, wash with warm water using mild detergent (or in accordance with the manufacturer's instructions).

Side effect
From the respiratory system: possible irritation of the mouth and throat, coughing, hoarseness, sore throat, dry mouth, thrush, rarely - paradoxical bronchospasm (usually due to incorrect inhalation technique).
From the digestive system: rarely - nausea, changes in taste sensations, oesophageal candidiasis.
CNS: Rarely - headache, anxiety, motor restlessness, depression, changes in behavior.

Other: rarely - petechiae.

When used in high doses (more than 2000 micrograms) may develop systemic effects of corticosteroids.

Contraindications
pulmonary tuberculosis in an active form;
fungal, bacterial and viral infections of the respiratory system;
acute bronchospasm, asthmatic status (as a means of emergency care);
neastmatichesky bronchitis;
childhood and adolescence to 16 years;
hypersensitivity to the drug.

With caution is prescribed for cirrhosis of the liver, glaucoma, hypothyroidism, other bacterial and parasitic infections (including at amebiaze), osteoporosis.

Pregnancy and lactation

If necessary, use Benakorta during pregnancy and lactation (breastfeeding) should be related to the expected benefit to the mother and the potential risk to the fetus. Data on the allocation of budesonide in breast milk are not available.

Use in hepatic dysfunction

Patients with impaired liver function may increase the time spent budesonide in the body.

Designate caution in liver cirrhosis.

Cautions

Pre-inhalation agonists (salbutamol and its derivatives) expands the bronchi and improves intake of budesonide in the airways, thereby increasing its therapeutic effect. In bronchial asthma Benakort can be used in combination with beta2-agonists, cromoglicic nedokromilom acid or sodium, methylxanthines, and ipratropium bromide. Avoid getting solution for inhalation in the eye. Benakort in the form of solution for inhalation can be used in patients who can not apply the other formulations for inhaled corticosteroids (elderly and senile).

One dose of powder for inhalation contains 9.8 milligrams of sodium benzoate, used as a carrier of the active substance, it has antifungal activity and reduces the risk of respiratory tract candidiasis.

In the transition from inside the GCS on drug therapy Benakort as a solution to decrease the dose of inhaled corticosteroids for systemic use should be made very slowly and in small doses, because patients may initially experience symptoms not associated with asthma (such as rhinitis, eczema, sore muscles and joints) as well as fatigue, headaches, nausea, and vomiting.

Belosalic

Release form, composition and packing Belosalic 

Ointment for external use translucent, white, homogeneous. 1 g of betamethasone dipropionate 640 mcg, which corresponds to the contents of betamethasone 500 mcg salicylic acid 30 mg. Other ingredients: mineral oil, petrolatum.

Belosalik ® Lotion

Solution for external application transparent, colorless, viscous, with the smell of isopropanol. 1 g of betamethasone dipropionate 640 mcg, which corresponds to the contents of betamethasone 500 mcg salicylic acid 20 mg. Excipients: disodium edetate, hypromellose 4000 cps, sodium hydroxide, isopropyl alcohol, purified water.

Clinico-pharmacological group: drug with antiinflammatory and keratolytic action for topical use.

Pharmacological action

Drug with anti-inflammatory, antipruritic, antiproliferative, antimicrobial and keratolytic action for topical use. Betamethasone has anti-inflammatory, antiallergic, antipruritic and anti-proliferative effect.

When applied to the skin surface, betamethasone has a rapid and dramatic effect in the inflammation, reducing the severity of objective symptoms (erythema, edema, lihenifikatsiya) and subjective sensations (itching, irritation, pain). Salicylic acid at the expense of keratolytic action clears the lesion on the scales, promotes penetration of betamethasone into the skin, supports the acidic environment of skin, preventing the development of bacterial and fungal infections.

Pharmacokinetics

Data on the pharmacokinetics of the drug Belosalik not given.

Statement

Subacute and chronic dermatoses in which effective therapy is topical corticosteroids, and accompanied by hyperkeratosis and scaling, including:
psoriasis;
eczema (disgidroticheskaya, seborrheic tiloticheskaya);
neurodermatitis;
planus;
asbestovidny zoster;
chronic discoid lupus erythematosus;
ichthyosis and ichthyotic skin lesions;
seborrhea;
seborrheic dermatitis (scalp).

The drug in solution form for external use is indicated for use on the scalp, as well as children 6 months and older.

Dosing regimen

The drug is intended for outdoor use. A small amount of ointment or a few drops of a solution for outdoor applications spread evenly over the surface of the skin, gently rubbing. Multiplicity of use - 2 times / day in mild cases, enough single use. Duration of continuous treatment is usually limited to 3-4 weeks.

If you need a longer course of therapy is recommended to use the drug less often, for example, through the day.

In the treatment of chronic disease treatment should be continued for some time after the disappearance of all symptoms, a doctor's supervision to avoid relapse. During the year, may conduct repeated courses of therapy.

Side effect

Side effects are generally mild in nature. Dermatological reactions: may develop hypersensitivity reactions (itching, burning, redness), rarely - aknepodobnye changes, hypopigmentation, striae, skin atrophy, hypertrichosis, telangiectasia, secondary skin infections.

With long-term continuous use, and large areas of skin betamethasone can cause systemic side effects associated with the suppression of the adrenal cortex. With the development of hypersensitivity reactions or adverse drug reactions should be abolished.

Contraindications
lupus;
cutaneous manifestations of syphilis;
chickenpox;
Viral infections of the skin;
skin reactions post-vaccination;
open wounds;
trophic ulcers;
rosacea;
acne vulgaris;
Children under the age of 6 months (for ointment);
Hypersensitivity to betamethasone, salicylic acid or any of the supporting components of the drug.

Pregnancy and lactation

Use of the drug Belosalik (in the form of ointments and / or solution for external use) in pregnant women is allowed in cases where the intended benefits to the mother outweigh the risks to the fetus.

In such cases, the use of the drug should be brief and limited to small areas of skin. During the period of breast feeding drug use Belosalik possible under strict indications, but the drug should not be applied to the skin of the breast before feeding.

Cautions

The ointment is for external use on skin and / or scalp. Solution for external application is particularly suitable for use on the scalp. Solution is easily distributed over the surface of the skin, hair does not stick, leaves no visible marks and gives a sense of coolness. Avoid getting ointment or solution for topical use in the eyes and mucous membranes. Not recommended for prolonged use of ointments on the skin of a person in connection with possible development of dermatitis by the type of rosacea, perioral dermatitis, atrophy of skin and acne.

Should avoid use of the drug in the anogenital region. It is not recommended to use the drug under occlusive dressing, except when necessary. With the development of fungal or bacterial flora of the skin, additional use of antibacterial or antifungal agents.

Use in pediatrics

Use of the drug Belosalik children should be as short as possible under strict precautions because in children there is a risk the system suction proportionally larger number of active components due to the dominance area of skin on body weight and lack of maturity of the epidermis.

You should not use the drug in children under the bandages and, particularly under the plasticized diapers, which can increase the risk of adverse events.

Effects on ability to drive vehicles and management mechanisms

Data on the adverse effects of the drug Belosalik on ability to drive vehicles and machines are not available.

Overdose

With long-term continuous use of a combination of betamethasone and salicylic acid, especially in children, the vast surface of the skin, when applied to skin with impaired integrity or use under occlusive dressings, it is possible increased absorption of active ingredients and a manifestation of systemic effects (secondary adrenal failure, hypercortisolism, Itsenko syndrome-Cushing).

Treatment: It is recommended repeal of the drug and symptomatic therapy.

Drug Interactions

There were no clinically significant interactions with other drugs. Simultaneous use of cosmetics and dermatological resources for treatment of acne, products containing ethanol, or a medical soap with a strong Dries up oily effect, can in certain cases, cause skin irritation.

Conditions and terms of

The drug should be stored in a place inaccessible to children at or above 25 ° C. Shelf Life ointment - 4 years, solution for external application - 2 years.

Beladerm

Release form, composition and packing Beladerm 

Cream for external use only 0.05% of white, homogeneous, without mechanical impurities. 1 g of betamethasone dipropionate 640 mcg, which corresponds to the contents of betamethasone 500 mcg. Excipients: hlorokrezol, sodium dihydrogen phosphate monohydrate, phosphoric acid, petroleum jelly white mineral oil, macrogol tsetostearat, cetostearyl alcohol (60% cetyl alcohol, stearyl alcohol 40%), sodium hydroxide and water.

Ointment for external use only 0.05% of white, translucent, homogeneous. 1 g of betamethasone dipropionate 640 mcg, which corresponds to the contents of betamethasone 500 mcg Excipients: Mineral oil, petroleum jelly white.

Clinico-pharmacological group: SCS for outdoor use.

Pharmacological action

SCS for outdoor use. Has anti-inflammatory, antipruritic, antiallergic, vasoconstrictor, antiexudative and antiproliferative activity.

When applied to the skin surface, the drug has a rapid and dramatic effect in the inflammation, reducing the severity of objective symptoms (erythema, edema, lihenifikatsiya) and subjective sensations (itching, irritation, pain).

Pharmacokinetics

Data on the pharmacokinetics of the drug Beloderm not given.

Statement

Conditions for which effective treatment with topical corticosteroids, including:
atopic dermatitis;
neurodermatitis;
allergic contact dermatitis;
eczema (various forms);
contact dermatitis (including professional);
non-allergic dermatitis (including solar and radiation dermatitis);
reactions to insect bites;
psoriasis;
Bullous dermatosis;
discoid lupus erythematosus;
planus;
exudative erythema multiforme;
pruritus of different etiologies.

Dosing regimen

The drug is intended for external use only. Cream or ointment for topical application is applied to the affected skin with a thin layer 2 times a day, a little rubbing. At sites with more dense skin (eg elbows, hands and feet) as well as places from which the drug is easily erased, the drug can be applied more frequently.

Duration of continuous treatment is usually less than 4 weeks. For relapse prevention in the treatment of chronic diseases, the therapy should continue for some time after the disappearance of all symptoms. During the year, may conduct repeated courses of therapy.

Cream for external use is used for the treatment of acute, including weeping skin lesions.

Ointment for external use is intended for the treatment of subacute and chronic dermatoses, including dry, scaly lesions and lihenizirovannyh, or in cases where it is necessary occlusal force ointment.

Side effect

Side effects are generally mild in nature.

Dermatological reactions: seldom - hypersensitivity reactions (itching, burning, redness), aknepodobnye changes, hypopigmentation, striae, skin atrophy, hypertrichosis, telangiectasia, secondary skin infections. With the development of hypersensitivity reactions or adverse drug reactions should be abolished.

Contraindications
lupus;
cutaneous manifestations of syphilis;
chickenpox;
viral, bacterial and fungal infections of the skin;
skin reactions post-vaccination;
open wounds;
trophic ulcers;
rosacea;
acne vulgaris;
tumors of the skin and subcutaneous structures;
Children up to age 6 months;
Hypersensitivity to betamethasone or any of the supporting components of the drug.

Pregnancy and lactation

Use of the drug in pregnant Beloderm allowed in cases where the intended benefits to the mother outweigh the risks to the fetus. In such cases, the use of the drug should be brief and limited to small areas of skin.

During the period of breastfeeding drug may under strict indications, but the drug should not be applied to the skin of the breast before feeding.

Cautions

Not recommended for long-term use on the face, because may develop rosacea, perioral dermatitis and acne. The drug should not be applied around the eyes, in connection with the probability of getting the drug on the mucosa, which may contribute to the development of cataracts, glaucoma, fungal infections of the eye and exacerbation of HSV infection.

Some parts of the body such as armpits, inguinal folds, where there is a natural occlusion, a greater risk of stretch marks, so use of the drug in those areas of the skin should be short.

With the development of fungal or bacterial infection of the skin, additional use of antibacterial or antifungal agents.

Use in pediatrics

The drug can be used in children from 6 months with caution and for the shortest period of time.

You should not use the drug under the bandages and, particularly under the plasticized diapers, because it enhances the absorption of the drug and increases the risk of side effects.

Effects on ability to drive vehicles and management mechanisms

Data on the adverse effects of the drug Beloderm on ability to drive vehicles and machines are not available.

Overdose

With long-term continuous use of the drug, especially among children, the vast surface of the skin, when applied to skin with impaired integrity or use under occlusive dressings may develop side effects associated with suppression and insufficiency of the adrenal cortex.

Treatment: It is recommended to cancel the product and if necessary, appoint a symptomatic therapy.

Drug Interactions

Drug interactions Beloderm with other drugs is unknown.

To the top of

The drug is approved for use as a means OTC.

Conditions and terms of

The drug should be stored in a place inaccessible to children at or above 25 ° C. Shelf life - 4 years.

Belogent

Release form, composition and packing Belogent 

Cream for external use only white, homogeneous, without mechanical impurities. 1 g of betamethasone dipropionate 640 mcg, which resp. content of betamethasone 500 mcg gentamicin (in the form of sulfate) 1 mg. Excipients: hlorokrezol, sodium dihydrogen phosphate monohydrate, phosphoric acid, petroleum jelly white mineral oil, macrogol cetostearyl ether 22, cetostearyl alcohol, sodium hydroxide, purified water.

Ointment for external use only white, translucent, homogeneous. 1 g of betamethasone dipropionate 640 mcg, which resp. content of betamethasone 500 mcg gentamicin (in the form of sulfate) 1 mg. Other ingredients: mineral oil, petroleum jelly white.

Clinico-pharmacological group: drug with anti-bacterial and anti-inflammatory effect for outdoor use.

Pharmacological action

Drug with anti-bacterial, anti-inflammatory and antiallergic effect for outdoor use. Betamethasone has anti-inflammatory, antiallergic, antipruritic and anti-proliferative effect.

When applied to the skin surface, betamethasone has a rapid and dramatic effect in the inflammation, reducing the severity of objective symptoms (erythema, edema, lihenifikatsiya) and subjective sensations (itching, irritation, pain). Gentamicin has a broad spectrum bactericidal activity against most gram-positive and Gram-negative microorganisms, including strains of Streptococcus spp. (Beta-hemolytic, alpha-hemolytic), Staphylococcus aureus (coagulase positive, coagulase-negative and some strains of penicillinase producing), Proteus spp., Escherichia coli.

Pharmacokinetics

Data on the pharmacokinetics of the drug Belogent not given.

Statement

Dermatitis, allergic and inflammatory skin diseases for which effective treatment with topical corticosteroids, and within which is complicated by bacterial infection or a risk of its accession, including:
eczema;
atopic dermatitis;
diffuse neurodermatitis;
contact (including professional) dermatitis;
atopic dermatitis;
seborrheic dermatitis;
impetigo;
psoriasis;
planus;
flebotodermii;
anogenital pruritus;
infected dermatitis (for example, evolved as a result of insect bites).

The drug can be used in children from 1 year.

Dosing regimen

The drug is intended for external use only. Cream or ointment for topical application is applied to the affected area with a thin layer in an amount necessary to cover the surface area, 2 times a day, a little rubbing. At sites with more dense skin (eg elbows, hands and feet) as well as places from which the drug is easily erased, Belogent can be applied more frequently.

Duration of continuous treatment is usually less than 4 weeks. For relapse prevention in the treatment of chronic therapy should continue for some time after the disappearance of all symptoms. During the year, may conduct repeated courses of therapy.

Cream for external use is used for the treatment of acute, including weeping skin lesions.

Ointment for external use is intended for the treatment of subacute and chronic dermatoses, including dry, scaly lesions and lihenizirovannyh.

Side effect

Side effects are generally mild in nature.

Dermatological reactions: seldom - hypersensitivity reactions (itching, burning, redness), aknepodobnye changes, hypopigmentation, striae, skin atrophy, hypertrichosis, telangiectasia. With the development of hypersensitivity reactions or adverse drug reactions should be abolished.

Contraindications
Viral infections of the skin;
skin reactions post-vaccination;
open wounds;
trophic ulcers;
acne vulgaris;
rosacea;
chickenpox;
cutaneous manifestations of syphilis;
lupus;
Hypersensitivity to betamethasone, gentamicin or to any of the supporting components of the drug.

Pregnancy and lactation

Use of the drug in pregnant Belogent possible only in cases where the intended benefits to the mother outweigh the risks to the fetus. In such cases, the use of the drug should be short and possibly beyond small patches of skin.

During the period of breast feeding drug use Belogent possible under strict indications, but the drug should not be applied to the skin of the breast before feeding.

Cautions

Not recommended for long-term use on the face, because may develop rosacea, perioral dermatitis and acne. The drug should not be applied around the eyes, in connection with the probability of getting the drug on the mucosa, which may contribute to the development of cataracts, glaucoma, fungal infections of the eye and exacerbation of HSV infection. Some parts of the body such as armpits, inguinal folds, where there is a natural occlusion, a greater risk of stretch marks, so use of the drug in those areas of the skin should be short.

In cases of fungal flora on the skin, additional use of antifungal agents.

Use in pediatrics

Belogent can be used in children with care and for the shortest period of time. You should not use the drug in children under the bandages and, particularly under the plasticized diapers, because it enhances the absorption of the drug and increases the risk of side effects.

Effects on ability to drive vehicles and management mechanisms

Data on the adverse effects of the drug's ability to operate vehicles and machinery not available.

Overdose

With long-term continuous use of the drug, especially among children, the vast surface of the skin, causing the skin to the tampering with or use under occlusive dressings may develop side effects associated with increased resorption of betamethasone or gentamicin. It should be stressed that the likelihood of such events extremely low.

Treatment: It is recommended to cancel the product and if necessary, appoint a symptomatic therapy.

Drug Interactions

Drug interactions Belogent with other drugs is unknown.

Conditions and terms of

The drug should be stored in a place inaccessible to children at or above 25 ° C. Shelf life - 4 years.

Bellacehol

Release form, composition and packing Bellacehol 

Tablets, coated yellow, biconvex forms. 1 tab. amount of alkaloids belladonna 150 mcg tanatsehol (with a total flavonoid and phenol carbonic acids in terms of lutein and dry matter 50%) 50 mg. Excipients: lactose, potato starch, calcium stearate, Aerosil A-380. The composition of the shell: sugar, gelatin, Aerosil A-380, Magnesium Hydroxide, Titanium Dioxide, tropeolin-On.

Clinico-pharmacological group: drug with choleretic and spasmolytic effect.

Pharmacological action

Combined medication. Possesses antiulcer action due to vagal blockade on gastric secretion, antispasmodic, analgesic, and reparative action. Normalizes the functional activity of the liver, stimulates bile secretion, and improves the biochemical composition of bile.

Pharmacokinetics

Data on the pharmacokinetics Bellatsehol not given.

Statement

In the combined therapy:
exacerbation of chronic gastritis and / or gastroduodenitis (incl. zrozivno-ulcerative changes);
gastric ulcer and duodenal ulcer, combined with chronic cholecystitis, gipomotornoy biliary dyskinesia.

Dosing regimen

Oral, 1 tab. 3 times / day for 20-30 minutes before eating. In case of need, and with good endurance can increase the daily dose of 6 tab.

Length is determined by your doctor, individually and as a rule, is 3-4 weeks.

Side effect

Maybe: allergic reactions, dry mouth. When used in high doses: accommodation disturbance, difficulty urinating.

Contraindications
glaucoma;
prostate adenoma;
tachyarrhythmia;
hyperthyroidism;
heart failure;
pyloric stenosis;
cholelithiasis;
pregnancy;
Lactation (breastfeeding);
childhood and adolescence to 18 years;
hypersensitivity to the drug.

Overdose

Symptoms: dry mouth, thirst, constipation, feeling of palpitation, mydriasis, transient blurred vision, photophobia, redness of skin, intestinal atony, urinary retention, headache, dizziness, fever, and in rare cases - psychomotor agitation, convulsions.

Treatment: gastric lavage, symptomatic therapy.

Drug Interactions

Reduces the effect of m-holinomimetikov and anticholinesterase drugs.

Conditions and terms of

List B. The drug should be kept away from children, dry, dark place at temperatures not above 25 ° C. Shelf life - 2 years.

Bellasthesinum

Structure and Composition Bellasthesinum 

Extract of belladonna deep (1:10) - 15 mg of benzocaine - 300 mg.

Other ingredients: microcrystalline cellulose, sodium carboxymethylcellulose, sodium croscarmellose, calcium stearate, kopovidon, mannitol.

Pharmacological action

Bellastezin - the combined product, which includes an extract of belladonna, and benzocaine. Providing analgesic and antispasmodic effect.

Analgesic effect is caused by a surface active local anesthetic benzocaine, spasmolytic - alkaloids belladonna (Atropa belladonnae L.). Indications spasms of smooth muscles of the digestive tract, biliary tract spasm, hypersecretory gastritis, hypersalivation. Dosage regimen for adults designate the interior of 1 tablet 3 times a day.

Pills swallowed without chewing, drinking 200 ml of water.

Used only in patients aged over 14 years. Bellastezin designed for short symptomatic therapy, therefore, duration of treatment set individually.

If symptoms persist for 3-5 days, it is necessary to decide whether further use of the drug.
Contraindications Hypersensitivity to benzocaine, herb medicines and other components of the drug;
stenosing diseases of the digestive tract;
atony of the intestines, atonic constipation;
Acute ulcerative colitis;
mechanical bowel obstruction;
pronounced atherosclerosis;
tachyarrhythmia;
acute bleeding;
myasthenia gravis;
glaucoma or suspected glaucoma;
benign prostatic hyperplasia;
age 14 years.

Side effect

Bellastezin generally well tolerated, but sometimes you have the following side effects.
CNS: headache, dizziness, nervousness, drowsiness, agitation (particularly in older patients), weakness, sleep disturbances, ataxia (ataxia), speech disorder.
From the digestive tract: dry mouth, loss of taste, anorexia, constipation.
On the part of the vision: mydriasis.
From the CVS: tachycardia.

Other: may cause allergic reactions.

Pregnancy and lactation

Cautions use during pregnancy is only possible if the expected benefit to the mother justifies the potential risk to the fetus. During the period of drug treatment is recommended to stop breast-feeding.

The drug is not recommended to take entities whose activities require a high concentration, speed of mental and physical reactions. Clinical data on efficacy and safety of the drug in children under the age of 14 are not available, so apply Bellastezin patients in this age group is not recommended.

Drug Interactions

Bellastezin reduces the antibacterial activity of sulfonamides. Amantadine and quinidine Bellastezina enhance the effect.

While the application Bellastezina with opioid analgesics and drugs depressing the central nervous system, possibly threatening CNS depression;
with haloperidol and organic nitrates - increased intraocular pressure, with SCS for systemic use - reduces the effect of corticosteroids and may increase intraocular pressure;
M-holinoblokatorami - enhanced anticholinergic effect;
with furosemide - possible orthostatic hypotension.

Reserpine, MAO inhibitors, guanetidin, antacid, ascorbic acid, attapulgite reduces the effect of Bellastezina.

While the application Bellastezina with antihistamines antihistamine increases the effect of c-adrenergic blockers - reduces the effect of the latter; with hormonal contraception - contraceptive effect is reduced, with nonselective inhibitors of reverse neuronal capture of monoamines - increased sedative effect. Bellastezin reduces the effect of NSAIDs, griseofulvin, digitoksina, doxycycline, ketoconazole, metoclopramide, metronidazole, enhances the effect of indapamide, nizatidina.

While the application Bellastezina with preparations containing potassium, possibly ulcers in the intestine.

Overdose

Symptoms: nausea, vomiting, tachycardia, tachyarrhythmias, myocardial ischemia, impotence, suppression of lactation, allergic reactions, hyperthermia, decreased sweating. Treatment - symptomatic.

Storage conditions and expiration dates

In a dry, dark place for up to 25 ° C.

Bellasthesin

Release forms - tablets (glass tubes) Bellasthesin 

Pharmacotherapeutic group - antispasmodic

Pharmacological action
mestnoanesteziruyuschee
spasmolytic

Ingredients - Benzocaine 0.3 g, 15 mg of belladonna extract

Statement
Pain in the abdomen and pelvis
Pain, localized in the upper abdomen
Diseases of the gallbladder, biliary tract and pancreas
Symptoms and signs involving the digestive system and abdomen
Other and unspecified abdominal pain
Cholelithiasis

The composition of the components
belladonna extract
benzocaine

Pharmacodynamics

Combined preparation has antispasmodic, mestnoanesteziruyuschee and analgesic action, reduces the acidity of gastric juice, the tone of smooth muscle cells of the digestive tract.

Application

Stomachodynia, gastric, bile, intestinal colic.

Dosing regimen

Oral, 1 tablet 2-3 times daily.

Side Effects

Dry mouth, drowsiness, dizziness, tachycardia, mydriasis, accommodation paresis, and allergic reactions.

Contraindications

Hypersensitivity, angle-closure glaucoma, prostate adenoma.

Cautions

With carefully administered to persons whose activities require high visual acuity.

Bellalgin

Release forms - tablets (banks of dark glasses) Bellalgin 

Pharmacotherapeutic group - analgesic (NSAID + local anesthetic) and antispasmodic

Pharmacological action
analgesic
antacid
mestnoanesteziruyuschee
spasmolytic

Ingredients - metamizol 0.25 g, 0.25 g of benzocaine, belladonna extract 15 mg, sodium bicarbonate 0.1 g

Statement
Gastritis and duodenitis
Gastritis, unspecified
Gastrojejunal ulcer
Gastroduodenitis unspecified
Alcoholic gastritis
Pain in the abdomen and pelvis
Pain, localized in the upper abdomen
Pain, localized in other areas of the lower abdomen
Diseases of the digestive
Diseases of the esophagus, stomach and duodenum
Crohn's Disease
Heartburn
Common symptoms and signs
Acute hemorrhagic gastritis
Noninfectious gastroenteritis and colitis, unspecified
Noninfectious enteritis and colitis
Peptic ulcer unspecified location
Symptoms and signs involving the digestive system and abdomen
Vascular diseases of intestines
Vascular disease intestine unspecified
Chronic gastritis, unspecified
Chronic atrophic gastritis
Chronic superficial gastritis
Chronic vascular disease
Other gastritis
Other diseases of intestines
Other diseases of intestines
Other diseases of esophagus
Other and unspecified abdominal pain
Other acute gastritis
Other noninfectious gastroenteritis and colitis
Dyspepsia
Intestinal ulcer
Ulcer of the esophagus
Duodenal ulcer
Gastric ulcer
Ulcerative colitis

The composition of the components
belladonna extract
benzocaine
Sodium bicarbonate
metamizol

Application

Diseases of the digestive tract, accompanied by the increased acidity of gastric juice, pain (heartburn, belching, stomachodynia, giperatsidnyh gastritis, gastric ulcer and duodenal ulcer, spastic colitis, a spasm of smooth muscles of the digestive tract.

Dosing regimen

Inside, before meals and 1 tablet 2-3 times daily. The highest single dose for adults 3 tablets daily - 10 tablets. Duration of treatment is established by your doctor.

Side Effects

Dry mouth, thirst, constipation, drowsiness, dizziness, mydriasis, accommodation paresis.

Contraindications

Angle-closure glaucoma, prostate adenoma.

Cautions

Avoid using drugs to persons whose work requires high visual acuity.

Bellaverin

Release forms Bellaverin - tablets (package outline Valium, Valium outline package) 

Pharmacotherapeutic group - antispasmodic

Pharmacological action  
m-anticholinergic
spasmolytic

Ingredients - belladonna extract 15 mg, papaverine hydrochloride 20 mg, excipients (calcium stearate, potato starch, sucrose)

The composition of the components
belladonna extract
calcium stearate
potato starch
papaverine
sucrose (Saccharum)

Belara

Release form, composition and packing

Tablets, film-coated 1 tab. hlormadinon (in the form of acetate) 2 mg ethinyl estradiol 30 mcg. Other ingredients: povidone, corn starch, magnesium stearate, lactose monohydrate.

Clinico-pharmacological group: monophasic oral contraceptive with antiandrogenic properties.

Pharmacological action

Combined contraceptive drug for oral administration. Part of the preparation hlormadinon - progestogen with antiandrogenic properties. Daily dose hlormadinona providing complete suppression of ovulation, is 1.7 mg. Required dose per cycle - 25 mg.

The mechanism of antiandrogenic action associated with the ability to act on specific receptors of the androgens. Ethinylestradiol - a synthetic estrogen, inhibits the secretion of the sebaceous glands of skin, increases the production of binding globulin sex hormone that reduces the amount of free testosterone in blood plasma. Long-term (more than 21 days) use of the drug leads to a decrease in the secretion of follicle stimulating and luteinizing hormones and, consequently, to suppress ovulation and endometrial proliferation and secretory transformation. Simultaneously change the properties of cervical mucus, which is accompanied by difficulty in passing the sperm through the cervical canal and a violation of their mobility.

Receiving Belar helps normalize the menstrual cycle, reduction of blood loss during menstruation, reduce the intensity of premenstrual pains. On the background of the drug may reduce the incidence of iron deficiency anemia, dysmenorrhea, functional ovarian cysts, ectopic pregnancy.

Pharmacokinetics

Suction

After receiving the drug inside hlormadinon and ethinyl estradiol is rapidly and completely absorbed from the gastrointestinal tract. Hlormadinona Cmax achieved within 1-2 hours

Metabolism and Elimination

Hlormadinona metabolites excreted in urine and bile in the ratio 4:6; T1 / 2 is 34 hours Ethinylestradiol biotransformed in the body to form sulfates and glyukuronatov. Ethinyl estradiol metabolites excreted in urine and bile in the ratio 4:6; T1 / 2 was approximately 25 h. Indications - contraception.

Dosing regimen

The drug is starting to take a 1-day menstrual cycle and continue to receive daily (preferably at the same time) within 21 days. Then should make a 7-day break, during which time the bleeding should start bleed.

After a 7-day break should resume taking the drug from the blister, regardless of whether the bleeding has stopped bleed or not. If hormonal contraceptives are not used during the previous menstrual cycle, pill should be started on the first day of normal menstrual cycle (first day of menstruation). Contraceptive action begins with the first day of admission.

If your period lasts longer than one day, the first pill should be taken at the 5 th day of menstruation, regardless of whether or not the bleeding has stopped. In this case, you should use additional, non-hormonal methods of contraception during the first 7 days.

If since the beginning of menstruation has been more than 5 days, then the woman is recommended to start taking the drug with the next menstrual cycle. When switching from another hormonal contraceptive that contains 21 active tablets, you should finish taking all the tablets of the old packaging.

Belar first pill to be taken the next day. There should be no break in the pill, the patient should not wait until the next menstrual cycle. When switching from other hormonal contraceptives containing 28 tablets, the first pill Belarus should take the next day after taking the last active tablet from the packaging prior contraceptive drug (ie after taking 21 active pills). There should be no break in the pill, the patient should not wait until the next menstrual cycle.

In the transition from contraceptives containing only progestin (mini-pill), a woman can start taking the drug Belarus in every day (without break) during the transition from the use of an implant containing the progestogen - the day of his removal, the transition from progestogens in injection form - the date on which should be made following injection. In all cases it is necessary to use additional barrier methods of contraception during the first 7 days of dosing of Belarus. After the abortion I trimester of pregnancy should begin taking the drug immediately after the abortion.

Additional methods of contraception are not required. After birth, women who are not breastfeeding can start taking the drug Belarus at the 21-day 28 postpartum. In this case, additional contraceptive measures should not be taken. If use of the drug in the postpartum period commenced after 28 days after birth, it is necessary to take additional contraceptive measures for 7 days.

If a woman has had sex, then prior to use of the drug to exclude pregnancy and wait until the next menstrual cycle. If the patient has not taken the drug in the usual time, and after the set time of reception is less than 12 hours, the contraceptive effect of the drug remains, and should take the missed tablet as soon as possible.

The next tablet should be taken at the scheduled time. If after a set time receiving more than 12 hours may decrease contraceptive effect of the drug. Should immediately take the missed pill and then continue taking medication at the usual time.

It is necessary to use additional barrier methods of contraception for the next 7 days. If within the 7 days pill box over, then taking pills from the next pack should be started immediately after the pills in the previous package, ie not a break between taking pills from a variety of packages.

If there was no bleed bleeding after the second pack, you should exclude pregnancy. If you experience vomiting or diarrhea while taking tablets of the drug Belar recommended additional methods of contraception, as contraceptive effect of the drug may be reduced due to incomplete removal of active drug substances in the intestine. The tablets should be swallowed whole, opting for one pill that is marked appropriately day of the week. The choice is determined by the direction of the arrow tabs on the packaging.

Side effect
Cardio-vascular system: increased blood pressure, increased risk of thromboembolic disease of the arteries and veins.
From the digestive system: nausea, vomiting, gastro-intestinal disturbances, destruction of bile ducts, liver neoplasms (benign and malignant).
CNS: depression, irritability, headache, blurred vision, tinnitus.
From the genital system: breast engorgement, vaginal discharge, dysmenorrhea.

Dermatological reactions: chloasma, skin dryness, rash, itching, acne, seborrhea.

Other: allergic reactions, back pain.

Contraindications
venous or arterial thrombosis (including history);
Severe or multiple risk factors for thrombosis;
diabetes mellitus with angiopathy;
severe liver disease (including history) to the normalization of liver tests;
Dubin-Johnson syndrome;
Rotor syndrome;
benign or malignant liver tumors (including history);
sickle-cell anemia;
porphyria;
expressed lipid metabolism;
severe arterial hypertension;
atherosclerosis;
migraine;
epilepsy;
hormone-malignant diseases of genital organs or breasts (including suspects);
vaginal bleeding of unknown etiology;
idiopathic jaundice or itching during previous pregnancy;
otosclerosis with hearing loss during the previous pregnancy;
pregnancy (including suspects);
Lactation (breastfeeding);
hypersensitivity to the drug.

Pregnancy and lactation

Belar drug is contraindicated in pregnancy. The drug should be discontinued as soon as pregnancy is diagnosed. Use of the drug in early pregnancy is not an indication for therapeutic abortion. According to available data to date is not noted an increased risk of malignant neoplasms in infants whose mothers used the drug during pregnancy.

Not recommended for drug Belarus during breastfeeding, because the background of his admission fewer milk supply, and changes its texture. While taking the drug during lactation, active substances in small amounts may be excreted in breast milk.

Data that they have a negative impact on the newborn, no.

Use in hepatic dysfunction

Caution should be applied Belarus with renal failure.

Use in renal impairment

Contraindicated in severe liver disease (including history) to the normalization of liver tests.

Cautions

Before the appointment of the drug and at least 1 time per year during its regular use should be a medical examination to exclude possible contraindications.

Becotide

Release form, composition and packing

Aerosol metered dose for inhalation as a clear, colorless solution; aluminum inhaler must be hermetically sealed with a metering valve and have no signs of corrosion. 1 dose of beclomethasone dipropionate 50 micrograms. Other ingredients: glycerol, ethanol, anhydrous, norfluran (HFA-134a).

Aerosol metered dose for inhalation as a clear, colorless solution; aluminum inhaler must be hermetically sealed with a metering valve and have no signs of corrosion. 1 dose of beclomethasone dipropionate 250 mcg. Other ingredients: glycerol, ethanol, anhydrous, norfluran (HFA-134a).

Clinico-pharmacological group: corticosteroids for inhalation.

Pharmacological action

Corticosteroids for inhalation use. Beclomethasone dipropionate is a prodrug with weak tropic to GCS receptors. Under the action of esterases, it is converted into an active metabolite - beclomethasone-17-monopropionat, which has a pronounced local anti-inflammatory effect.

Pharmacokinetics

Suction

Inhalation method of administration (via metered-dose inhaler) are absorbed unchanged beclomethasone dipropionate into the systemic circulation through the lungs with negligible absorption of swallowed drug. Even before the intake occurs predominantly rotation beclomethasone dipropionate in its active metabolite beclomethasone-17-monopropionat. Systemic absorption occurs from the lungs and from the gastrointestinal tract by ingested part of the drug. The absolute bioavailability of beclomethasone-17-monopropionat from the lungs is approximately 60% of normal dose. Beclomethasone dipropionate is rapidly absorbed, its Cmax plasma levels observed after 0.3 h. The plasma concentration of beclomethasone-17-monopropionata grows slowly, Tmax was 1 hour

Increasing doses of inhaled accompanied by almost linear increase in systemic drug concentrations. Bioavailability of beclomethasone dipropionate by ingestion is negligible, but the bioavailability is formed in the digestive tract of beclomethasone-17-monopropionata is 40%.

Metabolism

Beclomethasone dipropionate is rapidly metabolized esterases that are present in most tissues. The main product of metabolism is the active metabolite beclomethasone-17-monopropionat. Form and inactive secondary metabolites beclomethasone-21-monopropionat and beclomethasone, but they are not an essential part of system maintenance drug.

Distribution

In equilibrium, Vd beclomethasone dipropionate is an average of 20 liters, beclomethasone-17-monopropionata much higher - 424 liters. Binding to plasma proteins is relatively high - 87%.

Breeding

The elimination of beclomethasone dipropionate and beclomethasone-17-monopropionata characterized by high plasma clearance (150 l / h and 120 l / h, respectively), with T1 / 2 0.5 h and 2.7 h, respectively.

If ingestion of approximately 60% of the dose of beclomethasone dipropionate is excreted in feces mainly in the form of free and conjugated polar metabolites within 96 hours with urine output of approximately 12% of the dose in the form of free and conjugated polar metabolites. Renal clearance of beclomethasone dipropionate and its metabolites is negligible.

Statement
basic therapy of bronchial asthma in adults and children over 4 years.

Dosing regimen

Bekotid intended only for inhalation use. Bekotida dose should be set individually.

Adults and children older than 12 years: the drug is prescribed in the initial dose, which depends on the severity of the disease. Bronchial asthma, lung flow - 200-600 mg / day in divided doses. Bronchial asthma, moderate flow - 600-1000 mg / day in divided doses.

Bronchial asthma is severe - 1000-2000 mg / day in divided doses. Depending on the individual response dose can be increased or reduced to optimum effect. Children aged 4 years and older: 400 mcg / day in divided doses.

Bekotid children should receive the initial dose, corresponding to the severity of their condition. Depending on the individual patient response, dose may be increased or reduced to optimum effect. The maximum daily dose is 500 mcg. Elderly patients and patients with renal or hepatic impairment dose adjustment is required.

Patients should be aware of the preventative action of the drug and the need for its regular use even in the absence of asthma symptoms. If a patient believes that short-acting bronchodilators are less effective or it needs more inhalations than usual, he should consult a doctor. If patients find it difficult to coordinate pressing the canister dispensing inhaler with inhalation, can be inhaled via a spacer Bekotid.

When treating young children for inhalation Bekotida more convenient to use a spacer "Baby-haler.

Side effect

The frequency of adverse reactions is presented in accordance with the following gradation: very common (≥ 10%), frequent (≥ 1% and <10%), sometimes (≥ 0.1% and <1%), rarely (≥ 0.01%, <0.1%) very rare (<0.01%).

Local reactions: very common - candidiasis of the mouth and throat (thrush), which increases the likelihood of the application Bekotida in doses exceeding 400 micrograms per day. Most likely to develop this complication in patients with high levels of antibodies to Candida in the blood, indicating that the pre-infection.

Some assistance in prevention could have a mouth rinse with water after each use of an inhaler. For the treatment of candidiasis during ongoing therapy Bekotidom antifungal properties can be used for topical application. Allergic reactions: sometimes - rash, urticaria, pruritus, erythema, very rare - swelling of the eyes, face, lips, pharynx.
On the part of the endocrine system: very rarely - Cushing's syndrome, Kushingoid appearance, suppression of the adrenal cortex, growth retardation in children and adults, reduced bone mineral density.
CNS: very rare - anxiety, sleep disturbances, behavior changes, including hyperactivity and irritability (predominantly in children).
Part of the respiratory system: often - hoarseness, throat irritation.

Some benefit in this case could have a mouth rinse with water immediately after inhalation. The use of a spacer reduces the likelihood of these side effects.

Very rare - a paradoxical bronchospasm, which manifests increased wheezing after ingalirovaniya drug. This state should be immediately docked by using fast-acting inhaled bronchodilator.

Application Bekotida should cease immediately and if necessary, appoint an alternative therapy.
On the part of the vision: cataract, glaucoma.

Contraindications
hypersensitivity to the drug.

Pregnancy and lactation

Use of the drug during pregnancy and lactation (breastfeeding) is possible only if the potential benefit to the mother outweigh the risks to the fetus or nursing child.

Use in hepatic dysfunction

Patients with hepatic impairment dose adjustment is required.

Use in renal impairment

Patients with renal impairment dose adjustment is required. Special instructions Bekotid not a means of relief of acute asthma attacks, and is used for regular treatment. Treatment of asthma should be conducted in accordance with the step program. Effect of treatment should be monitored clinically and by investigations of respiratory function.

Increased demand for acceptance of short β2-agonists adrenretseptorov to control symptoms indicate a worsening condition. In this case the patient's treatment plan should be reviewed.

In case of insufficient efficacy or severe exacerbation of asthma is necessary to increase doses of inhaled Bekotida and, if necessary, the appointment of systemic corticosteroids, and in the presence of infection - antibiotics. Sudden and progressive deterioration of asthma symptoms is a potentially life-threatening condition and requires increasing doses of corticosteroids. Necessary to verify implementation of patient inhalation technique, to be sure that pressing on the inhaler canister is synchronized with the breath and provides a smooth delivery of the drug into the lungs.

Systemic effects may occur when using any inhaled corticosteroids, especially for prolonged use at high doses. These effects were significantly more likely to develop in the appointment of oral corticosteroids. It is therefore particularly important to select the minimum dose of inhaled corticosteroids in control of the disease. Due to the possible dysfunction of the adrenal cortex of patients with the translation of treatment with oral forms of inhaled steroids on Bekotid should be under close medical supervision and regular monitoring of adrenal function.

With the addition of inhaled Bekotida discontinuation systemic steroids should be gradual, and ill recommend carry a warning card, which indicates that in stressful situations, the patient needs additional systemic corticosteroids. Sometimes translated from systemic corticosteroids to inhalation may lead to the appearance of previously repressed forms of allergy, such as allergic rhinitis or eczema.

Not recommended drastic cancellation Bekotida. As with the appointment of other inhaled corticosteroids, should be particularly careful when treating patients with active or inactive pulmonary tuberculosis. The product contains small amounts of ethanol and glycerol. In the range of therapeutic doses of the content of these substances is extremely low and poses no danger to patients. Daily administration of the propellant HFA-34a, which does not contain freon, different kinds of animals over 2 years showed that the substance used has no toxic effects even at very high concentrations far exceeding those that can be used by patients.

Babynos

Release forms  Babynos - oral drops (bottle, amber glass dropper) 30 ml 

Pharmacotherapeutic group - carminative herbal

Pharmacological action
carminative

Ingredients - Coriander Seed Extract 200 mg, Chamomile flower extract 200 mg, Fennel seed extract 320 mg, excipients (propylene glycol, saccharin sodium, sorbitol) - 1 g

Statement
Malabsorption in the gut
Pilorospazme, not elsewhere classified
Flatulence and related conditions
Somatoform dysfunction of the autonomic nervous system
Other diseases of stomach and duodenum
Other and unspecified abdominal pain

The composition of the components
chamomile flower extract
propylene glycol
saccharin
sorbitol
fennel fruit extract
extract of coriander seeds

Application

Bloating and cramping the gastrointestinal tract in infants (including those associated with the transition to artificial feeding), primary school children and the elderly.

Dosing regimen

Inside, undiluted or with a small amount of liquid; infants - 3-6 drops for children over 1 year - 6-10 drops to children of school age - 10-15 drops 3 times a day.

Side Effects

Skin and respiratory allergic reactions.

Contraindications

Hypersensitivity (including intolerance of sorbitol).

Batrafen

Release form, composition and packing Batrafen 

Gel for external use watery, almost white.

1 year tsiklopiroks 7.7 mg.

Other ingredients: 2-propanol, sodium docusate, octyldodecanol, dimethicone copolyol 190, carbomer 4,000,000, sodium hydroxide, water

Clinico-pharmacological group: antifungals for topical use.

Pharmacological action

Tsiklopiroks and its derivatives - tsiklopiroksolamin - antifungal agent wide spectrum of action. Tsiklopiroks has a broad spectrum fungicide (fungicide) action and is effective when applied topically on dermatomitsetov, yeasts, molds and other fungi (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton tonsurans, Trichophyton quinckeanum, Trichophyton equinum, Trichophyton concentricum, Trichophyton epilans , Trichophyton ferrugineum, Trichophyton gallnae, Trichophyton schoenleinii, Trichophyton soudanense, Trichophyton terrestre, Trichophyton violaceum, Microsporum canis, Microsporum gypseum, Microsporum audouini, Microsporum langeroni, Microsporum nanum, Epidermophyton floccosum, Candida (Candida albicans, Candida tropicalis, Candida krusei, Candida parapsilosis , Candida pseudotropicalis, Candida lipolytica, Candida quiliermondii, Candida brumpti, Candida utilis, Candida viswanathii), Cryptococcus neoformans, Histoplasma capsulatum, Sporotrichum schenckii, Torulopsis glabrata, Blastomyces dermatidis, Paracoccidioides braziliensis, Saccharomyces cerevisiae, Torula Bergeri, Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Penicillium chrysogenum, Penicillium notatum, Absidia corymbifera, Mucor miehei, Paecilomyces varioti, Fusarium solani, Madurella grisea, Madurella mycetomi, Allescheria boydii, Cladosporium carrionii, Cladosporium trichoides, Philophora jeanselmei, Philophora pedrosoi, Philophora gougeroti, Hormodendrum dermatidis, Pyrenochaeta romeroi , Leptosphaeria senegalensis, Scopulariosus brevicaulus, Malassezia furfur).

Tsiklopiroks also active against some strains of Gram-positive and most strains of Gram-negative bacteria acts bacteriostatic. Suppresses the development of mycoplasma and trichomonas.

Tsiklopiroks active against the major causative agents of onychomycosis. Nail polish is used to treat fungal nail infections. Most effective in the early stages of onychomycosis with distal type of nail infections (not more than one-half or one third of the nail), without involvement of the matrix, a superficial onychomycosis and aftercare of onychomycosis after systemic therapy to prevent relapse.

With multi-colored shingles clinical and mycological improvement is noted not earlier than 2 weeks of treatment Tsiklopiroksom.

Pharmacokinetics.

Tsiklopiroks (tsiklopiroksolamin) when applied topically to quickly penetrate the skin, its appendages and mucous membranes. After 1.5-6 hours after application, its concentration in these tissues exceed the minimum inhibitory concentrations (MIC) against pathogenic fungi many times (MIC for dermatophytes, fungi of the genus Candida, molds and yeasts - 0.98-3.9 mg / ml; IPC for mycoplasma and Trichomonas vaginalis - 7.8-31.3 mg / ml). When applying Tsiklopiroksa over a large surface (750 cm ^ 2) and for a long time (6 hours or more) can be detected in blood (1.3% dose), with 94-97% bound to plasma proteins, T1 / 2 is about 1.7 hours , excreted by the kidneys.

Tsiklopiroks nail polish. Tsiklopiroks begins to penetrate the nail plate during the first hours after application of varnish. Forms a physical barrier that prevents reinfection. When fungal nail penetration Tsiklopiroksa increases.

Tsiklopiroksa effective concentration in the nails of fingers reached after 7 days of treatment, but in the toenails feet - after 14 days of lecheniya.Dlya Tsiklopiroksa penetration into the deeper layers in contact with hyponychial pillow, it may take from 14 to 30 days. Tsiklopiroks accumulate in the nails of toes is 4 times more than the nails of fingers. Long deposited at the site of infection.

The effective concentration Tsiklopiroksa persists for 7-14 days after cessation of treatment. Tsiklopiroks detected in the serum after its application to the nails of all fingers.

Statement
tsiklopiroks (tsiklopiroksolamin) is used to treat fungal infections of the skin and mucous membranes caused by susceptible to the drug mushrooms: fungal infections of the skin, including multi-colored shingles, candidiasis (for the application of cream and a solution for outdoor applications);
vaginitis, vulvovaginitis, colpitis (including recurrent course), especially vaginal candidiasis (for use vaginal cream and suppositories);
mycosis of nails, or onychomycosis (for application of nail polish);
prevention of fungal infections (for application of powder).

Dosing regimen

For the treatment of fungal skin lesions Tsiklopiroks as a cream or solution applied to the affected skin areas 2 times a day. After applying the cream pinch of skin is dried. Solution Tsiklopiroksa rubbed into the skin. Treatment is usually continued for 2 weeks before the disappearance of all symptoms. Then, to prevent relapse Tsiklopiroks apply for another 1-2 weeks.

Avoid getting Tsiklopiroksa in the eye.

For the treatment of vaginitis, vulvovaginitis, colpitis usually used vaginal cream or vaginal suppositories Tsiklopiroksa. Cream injected deep into the vagina using the supplied tip at a dose of 5 g. 1 time a day at bedtime. Duration of treatment is determined individually, but it should not constitute more than 14 days. The clinical effect is usually observed after 6 days. In the event that simultaneously with colpitis noted skin lesions in the vagina, on this site cause vaginal cream Tsiklopiroksa with a cotton swab.

Vaginal suppositories appoint 1 suppository (100 mg), 1 a day for 3-6 days, depending on the severity of the disease. To prevent re-infection should be the simultaneous treatment of sexual partners.

For the treatment of onychomycosis Tsiklopiroks in the form of nail varnish applied 1 time per day with a thin layer on the affected nail. Before the first application was removed as much of the affected nail and napilivayut it with a nail file to create an uneven surface. Once a week the entire layer of varnish was removed using a conventional solvent, while seeking to remove as much of the affected material. During the second month of treatment is sufficient Half Tsiklopiroksa varnish applications per week, starting from the third month - once a week. Duration of treatment depends on the severity of injuries, but should not exceed 6 months, the average duration - about 12 weeks. During the treatment of onychomycosis is not recommended to use cosmetic nail varnish.

In order to prevent fungal infections in patients at high risk of their occurrence in the form of powder Tsiklopiroks recommend to pour into the socks and / or footwear, the duration of the use of powdered set individually

Side effect

Local allergic reactions (rare): itching and burning of the skin or mucous membranes at the site of application, the redness and peeling of the skin surrounding the affected nail.

Contraindications
idiosyncrasy (including history of hypersensitivity) tsiklopiroksa (tsiklopiroksolamina).
pregnancy and lactation;
children under 10 years of age.

Pregnancy and lactation

In pregnancy, drugs Tsiklopiroksa used only under strict indications (perhaps for reasons and under medical supervision).

Data about the safety of Tsiklopiroksa during lactation (breastfeeding) is not available

Cautions

Duration of application of varnish Tsiklopiroksa should not exceed 6 months; vaginal cream - 2 weeks. Lack of effect in the treatment of onychomycosis or ringworm within 4 weeks requires further diagnosis.

The use of drugs that improve blood circulation, vitamins, stimulants of immunity can reduce treatment time.

In the case of treatment of vaginitis / vulvovaginitis in order to prevent re-infection recommend simultaneous treatment of sexual partner. In order to prevent reinfection should strictly comply with the measures of general hygiene.

Onihomikozah therapeutic effect depends on the regular disinfection of shoes (gloves). If the damage clearcoat enough again to lubricate the damaged areas of the drug. Opened a bottle of nail polish can be stored at room temperature in a dark place for 3 months. With long-term external application Tsiklopiroksa possible phenomenon of sensitization (contact dermatitis).

In infants and toddlers, as well as during pregnancy Tsiklopiroks used only under strict indications.

Avoid getting products in the eye Tsiklopiroksa

Overdose

Currently, cases of overdose were reported Tsiklopiroksa

Drug Interactions

Not established clinically significant interactions Tsiklopiroksa (tsiklopiroksolamina) with other drugs.

During the treatment of onychomycosis is not recommended to use both the cosmetic nail varnish.

Effect Tsiklopiroksa increase systemic antifungal drugs (terbinafine, itraconazole, fluconazole

Conditions and terms of

Store in a dry place, protected from light, place inaccessible to children, at a temperature above 25 ° C.